

## Supporting Information

### Kinetic Resolution of *tert*-alcohols through S<sub>N</sub>2' Reaction Catalyzed by Chiral Bisphosphoric Acid/Silver(I) Salt-Combined System

Satavisha Kayal, Jun Kikuchi, Naoya Shinagawa, Shigenobu Umemiya, Masahiro Terada\*

e-mail: mterada@tohoku.ac.jp

Department of Chemistry, Graduate School of Science, Tohoku University,  
Aoba-ku, Sendai 980-8578, Japan.

#### Contents


1. General Information
2. Kinetic Resolution of *tert*-alcohol through Intramolecular S<sub>N</sub>2' Reaction
3. Preparation of substrates
4. Determination of the relative and absolute configuration
5. Determination of the reaction pathway of the intramolecular S<sub>N</sub>2' reaction
6. Stereochemical assignment of *trans*-**5t** and calculation of conversion *c* in Table 2, entry 19
7. Large scale experiment
8. Derivatization
9. Main reaction using catalyst (*R*)-**1b**
10. DFT calculation
11. NMR spectra
12. HPLC chart
13. Reference

## 1. General Information

All reactions were carried out under nitrogen atmosphere in flame-dried glassware. Dichloromethane ( $\text{CH}_2\text{Cl}_2$ ) and toluene were supplied from KANTO Chemical Co., Inc. as “Dehydrated solvent system”. Other solvents and reagents were purchased from commercial suppliers and used without further purification. Purification of reaction products was carried out by flash column chromatography using silica gel 60 N (Merck 40-63  $\mu\text{m}$ ). Analytical thin layer chromatography (TLC) was performed on Merck precoated TLC plates (silica gel 60 GF 254, 0.25 mm).  $^1\text{H}$  NMR spectra were recorded on a JEOL ECA-600 (600 MHz) spectrometer. Chemical shifts are reported in ppm from tetramethylsilane or solvent resonance as the internal standard ( $\text{CDCl}_3$ : 7.26 ppm, TMS: 0.00 ppm).  $^{13}\text{C}$  NMR spectra were recorded on a JEOL ECA-600 (151 MHz) spectrometer with complete proton decoupling. Chemical shifts are reported in ppm from the solvent resonance as the internal standard ( $\text{CDCl}_3$ : 77.16 ppm).  $^{19}\text{F}$  NMR spectra were recorded on JEOL ECA-600 (565 MHz) spectrometer with complete proton decoupling. Chemical shifts are reported in ppm from the  $\text{C}_6\text{H}_5\text{CF}_3$  (-67.2 ppm) resonance as the external standard. Infrared spectra were recorded on a Jasco FT/IR-4100 spectrometer. Chiral stationary phase HPLC analysis was performed on a Jasco LC-2000 Plus Series system with DACIEL chiral analytical column (4.6 mm $\Phi$ \* 250 mm length). Optical rotations were measured on a Jasco P-1020 digital polarimeter with a sodium lamp and reported as follows;  $[\alpha]_D^{25}$  ( $c = \text{g}/100 \text{ mL}$ , solvent, % ee). High resolution mass spectra analysis was performed on a Bruker Daltonics solariX 9.4T FT-ICR-MS spectrometer and a JEOL JMS-T100GCV Time-of-Flight Mass Spectrometer at the Research and Analytical Center for Giant Molecules, Graduate School of Science, Tohoku University.

## 2. Enantioselective Reaction of

Representative procedure for the kinetic resolution of *tert*-alcohols



To a mixture of MS 5Å (40.0 mg), (*R*)-**1a** (12.4 mg, 0.01 mmol, 10 mol%) and Ag<sub>2</sub>CO<sub>3</sub> (1.4 mg, 0.005 mmol, 5 mol%) was added Et<sub>2</sub>O (0.5 mL). The reaction mixture was stirred at room temperature for 15 min and then cooled at 0 °C. To the reaction mixture was added a solution of racemic (*E*)-**4** (0.1 mmol) in Et<sub>2</sub>O (0.5 mL) at the same temperature and the reaction mixture was stirred for 96 h. The reaction mixture was quenched with NEt<sub>3</sub> (10 μL) and directly purified by flash column chromatography (Hexane/EtOAc = 10:1) to give **5** and (*R,E*)-**4**. The enantiomeric excess was determined by chiral stationary phase HPLC analysis.


### (2*S*,3*R*)-2-methyl-2,3-diphenyl-3-vinyloxirane (**5a**)

**5a** 48% yield (11.3 mg); colorless oil; [ $\alpha$ ]<sub>D</sub><sup>26</sup> +69.5 (*c* 5.0, CHCl<sub>3</sub>, 98% ee); R<sub>f</sub> = 0.72 (Hexane/EtOAc = 4/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 7.15-7.11 (m, 4H), 7.08 (t, *J* = 7.6 Hz, 4H), 7.03-7.00 (m, 2H), 6.30 (dd, *J* = 17.2, 11.0 Hz, 1H), 5.40-5.33 (m, 2H), 1.80 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 140.5, 137.6, 136.3, 127.6, 127.5, 127.5, 126.8, 126.7, 126.4, 118.9, 71.5, 69.5, 20.5; IR (ATR): 2954, 2922, 2868, 2853, 1741, 1459, 1376, 803, 772 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>17</sub>H<sub>16</sub>NaO 259.1093, found: 259.1092; HPLC analysis: Chiralcel OD-3 column (Hexane:*i*PrOH = 99.5/0.5, 1.0 mL/min, 40 °C, 220 nm) 5.7 min (minor), 6.2 min (major). Configuration Assignment: The relative and absolute configurations were assigned as (2*S*,3*R*) by analogy with compound **5b**.


### (*R,E*)-4-hydroxy-3,4-diphenylpent-2-en-1-yl 2,2,2-trichloroacetimidate (**4a**)

**4a** 52% yield (20.7 mg); colorless oil; [ $\alpha$ ]<sub>D</sub><sup>25</sup> -31.7 (*c* 0.79, CHCl<sub>3</sub>, 88% ee); R<sub>f</sub> = 0.32 (Hexane/EtOAc = 4/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 8.20 (s, 1H), 7.43-7.41 (m, 2H), 7.32 (td, *J* = 7.6, 1.8 Hz, 2H), 7.26 (tt, *J* = 7.1, 1.8 Hz, 1H), 7.23-7.17 (m, 3H), 6.77-6.75 (m, 2H), 6.28 (t, *J* = 6.9 Hz, 1H), 4.56 (d, *J* = 6.9 Hz, 2H), 2.02 (s, 1H), 1.72 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 162.7, 152.3, 145.5, 136.5, 129.5, 128.2, 128.1, 127.7, 127.3, 126.0, 120.5, 91.6, 77.05, 67.3, 28.9; IR (ATR): 3338, 2981, 1660, 1298, 1073, 977, 822, 796, 700, 648 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>19</sub>H<sub>18</sub>Cl<sub>3</sub>NNaO<sub>2</sub> 420.0295, found: 420.0295; HPLC analysis: Chiralpak IA-3 column (Hexane:*i*PrOH = 95/5, 1.0 mL/min, 40 °C, 220 nm) 9.6 min (minor), 11.0 min (major). The absolute configurations were assigned as (*R*) by derivatization.


**(2*S*,3*R*)-2-methyl-3-phenyl-2-(4-(trifluoromethyl)phenyl)-3-vinyloxirane (5b)**

  
34% yield (10.3 mg); colorless oil;  $[\alpha]_D^{27} +136.3$  (*c* 0.82, CHCl<sub>3</sub>, 94% ee);  $R_f = 0.45$  (Hexane/EtOAc= 10/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  7.33 (d, *J* = 8.2 Hz, 2H), 7.26-7.24 (m, 2H), 7.10-7.07 (m, 4H), 7.04 (tt, *J* = 6.0, 2.4 Hz, 1H), 6.28 (dd, *J* = 17.2, 11.0 Hz, 1H), 5.42-5.33 (m, 2H), 1.79 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  144.6, 137.0, 135.7, 129.0 (q, *J* = 31.9 Hz), 127.8, 127.4, 127.2, 126.8, 124.6 (q, *J* = 4.4 Hz), 124.2 (q, *J* = 271.8 Hz), 119.5, 71.7, 69.0, 20.2; IR (ATR): 2954, 2922, 2868, 2853, 1734, 1459, 1376, 772 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>18</sub>H<sub>15</sub>F<sub>3</sub>NaO 327.0967, found: 327.0966; HPLC analysis: Chiralcel OD-3 column (Hexane:<sup>i</sup>PrOH = 99.9:0.1, 1.0 mL/min, 40 °C, 220 nm) 6.1 min (minor), 6.5 min (major). Configuration Assignment: The relative and absolute configurations were assigned as (2*S*,3*R*) by derivatization of **4a** and NOE analysis.


**(*R,E*)-4-hydroxy-3-phenyl-4-(4-(trifluoromethyl)phenyl)pent-2-en-1-yl 2,2,2-trichloroacetimidate (4b)**

  
47% yield (21.9 mg); colorless oil;  $[\alpha]_D^{25} -17.9$  (*c* 1.9, CHCl<sub>3</sub>, 81% ee);  $R_f = 0.35$  (Hexane/EtOAc= 4/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  8.23 (s, 1H), 7.56 (q, *J* = 8.9 Hz, 4H), 7.27-7.20 (m, 4H), 6.78-6.76 (m, 2H), 6.27 (t, *J* = 6.5 Hz, 1H), 4.59-4.53 (m, 2H), 2.06 (s, 1H), 1.75 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  162.7, 151.4, 149.7, 135.9, 129.52 (q, *J* = 33.2 Hz), 129.51, 128.4, 128.1, 126.4, 125.2 (q, *J* = 4.4 Hz), 121.9 (q, *J* = 273.5 Hz), 121.5, 91.6, 67.0, 29.2, one carbon was not found due to overlapping; IR (ATR): 3340, 2981, 1661, 1324, 1164, 1123, 1072, 797, 772 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>17</sub>Cl<sub>3</sub>F<sub>3</sub>NNaO<sub>2</sub> 488.0169, found: 488.0168.; HPLC analysis: Chiralpak IA-3 column (Hexane:<sup>i</sup>PrOH = 95/5, 1.0 mL/min, 40 °C, 220 nm) 8.5 min (minor), 10.1 min (major). The absolute configurations were assigned as (*R*) by analogy with compound **4a**.


**(2*S*,3*R*)-2-(4-chlorophenyl)-2-methyl-3-phenyl-3-vinyloxirane (5c)**

  
43% yield (11.6 mg); colorless oil;  $[\alpha]_D^{26} +175.05$  (*c* 0.7, CHCl<sub>3</sub>, 94% ee);  $R_f = 0.32$  (Hexane/EtOAc= 10/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  7.10-7.09 (m, 4H), 7.07-7.03 (m, 5H), 6.26 (dd, *J* = 17.2, 11.0 Hz, 1H), 5.40-5.31 (m, 2H), 1.76 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  139.1, 137.3, 135.9, 132.5, 127.8, 127.8, 127.7, 127.4, 127.1, 119.3, 71.6, 68.9, 20.3; IR (ATR): 2954, 2922, 2868, 1735, 1460, 1376, 772 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>17</sub>H<sub>15</sub>ClNaO 293.0704, found: 293.0703; HPLC analysis: Chiralpak OD-3 column (Hexane:<sup>i</sup>PrOH = 99.9:0.1, 1.0 mL/min, 40 °C, 220 nm) 8.4 min (minor), 9.1 min (major). Configuration Assignment: The relative and absolute configurations were assigned as (2*S*,3*R*) by analogy with compound **5b**.


**(*R,E*)-4-(4-chlorophenyl)-4-hydroxy-3-phenylpent-2-en-1-yl 2,2,2-trichloroacetimidate (4c)**

  
45% yield (19.5 mg); colorless oil;  $[\alpha]_D^{25} -28.9$  (*c* 1.58, CHCl<sub>3</sub>, 92% ee);  $R_f = 0.35$  (Hexane/EtOAc= 4/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  8.21 (s, 1H), 7.36 (td, *J* = 5.5, 3.2 Hz, 2H), 7.29 (dt, *J* = 8.9, 2.2 Hz, 2H), 7.25-7.20 (m, 3H), 6.77 (td, *J* = 4.8, 2.7 Hz, 2H), 6.26 (t, *J* = 6.5 Hz, 1H), 4.55 (dd, *J* = 6.9, 1.4 Hz, 2H), 1.99 (s, 1H), 1.71 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  162.6, 151.8, 144.1, 136.2, 133.2, 129.5, 128.4, 127.9, 127.5, 120.9, 91.5, 76.7, 67.1, 29.1; IR (ATR): 3338, 2978, 1661, 1490, 1300, 1219, 1091, 1013, 978, 771, 703, 649 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>19</sub>H<sub>17</sub>Cl<sub>4</sub>NNaO<sub>2</sub> 453.9906, found: 453.9905; HPLC analysis: Chiralpak IA-3 column (Hexane:<sup>i</sup>PrOH = 95/5, 1.0 mL/min, 40 °C, 220 nm) 9.8 min (minor), 11.8 min (major). The absolute configurations were assigned as (*R*) by analogy with compound **4a**.


### (2*S*,3*R*)-2-methyl-3-phenyl-2-(*p*-tolyl)-3-vinyloxirane (**5d**)

  
**5d**  
( $R^L = 4\text{-MeC}_6\text{H}_4$ ) 40% yield (10.0 mg); colorless oil;  $[\alpha]_{\text{D}}^{27} +137.4$  ( $c$  0.64,  $\text{CHCl}_3$ , 94% ee);  $R_f = 0.43$  (Hexane/EtOAc = 10/1);  $^1\text{H NMR}$  (600 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.14-7.08 (m, 4H), 7.05-7.01 (m, 3H), 6.88 (d,  $J = 7.6$  Hz, 2H), 6.29 (dd,  $J = 17.2, 11.0$  Hz, 1H), 5.38-5.30 (m, 2H), 2.17 (s, 3H), 1.77 (s, 3H);  $^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ ):  $\delta$  137.8, 137.5, 136.5, 136.3, 128.3, 127.6, 127.5, 126.7, 126.3, 118.8, 71.6, 69.4, 21.2, 20.6; IR (ATR): 2955, 2924, 2854, 1712, 1446, 812, 771, 700  $\text{cm}^{-1}$ ; HRMS(ESI)  $m/z$ :  $[\text{M}+\text{Na}]^+$  Calcd for  $\text{C}_{18}\text{H}_{18}\text{NaO}$  273.1250, found: 273.1249.; HPLC analysis: Chiralcel OD-3 column (Hexane:*i*PrOH = 99.5/0.5, 1.0 mL/min, 40 °C, 220 nm) 4.6 min (minor), 4.8 min (major). Configuration Assignment: The relative and absolute configurations were assigned as (2*S*,3*R*) by analogy with compound **5b**.


### (*R*,*E*)-4-hydroxy-3-phenyl-4-(*p*-tolyl)pent-2-en-1-yl 2,2,2-trichloroacetimidate (**4d**)

  
**4d**  
( $R^L = 4\text{-MeC}_6\text{H}_4$ ) 40% yield (16.5 mg); colorless oil;  $[\alpha]_{\text{D}}^{25} -9.14$  ( $c$  1.44,  $\text{CHCl}_3$ , 85% ee);  $R_f = 0.36$  (Hexane/EtOAc = 4/1);  $^1\text{H NMR}$  (600 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.20 (s, 1H), 7.32-7.30 (m, 2H), 7.24-7.18 (m, 3H), 7.13 (d,  $J = 7.6$  Hz, 2H), 6.78-6.77 (m, 2H), 6.28 (t,  $J = 6.9$  Hz, 1H), 4.56 (d,  $J = 6.9$  Hz, 2H), 2.36 (s, 3H);  $^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ ):  $\delta$  162.7, 152.5, 142.5, 136.9, 136.6, 129.5, 128.9, 128.1, 127.7, 125.9, 120.2, 91.6, 76.9, 67.3, 28.8, 21.2; IR (ATR): 3340, 2979, 1660, 1291, 1075, 976, 819, 794, 772, 703, 647  $\text{cm}^{-1}$ ; HRMS(ESI)  $m/z$ :  $[\text{M}+\text{Na}]^+$  Calcd for  $\text{C}_{20}\text{H}_{20}\text{Cl}_3\text{NNaO}_2$  434.0452, found: 434.0451.; HPLC analysis: Chiralpak IA-3 column (Hexane:*i*PrOH = 95:5, 1.0 mL/min, 40 °C, 220 nm) 9.5 min (minor), 11.6 min (major). The absolute configurations were assigned as (*R*) by analogy with compound **4a**.


### 3-(4-methoxyphenyl)-3-phenylpent-4-en-2-one (**6e**)

  
**6e**  
( $R^L = 4\text{-MeOC}_6\text{H}_4$ ) 48% yield (12.8 mg); colorless oil;  $R_f = 0.58$  (Hexane/EtOAc = 4/1);  $^1\text{H NMR}$  (600 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.33 (t,  $J = 7.6$  Hz, 2H), 7.30-7.27 (m, 1H), 7.14-7.12 (m, 2H), 7.06-7.04 (m, 2H), 6.88-6.86 (m, 2H), 6.75 (dd,  $J = 17.2, 11.0$  Hz, 1H), 5.39 (d,  $J = 11.7$  Hz, 1H), 4.75 (d,  $J = 17.2$  Hz, 1H), 3.81 (s, 3H), 2.16 (s, 3H);  $^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ ):  $\delta$  206.9, 158.7, 140.8, 140.5, 132.4, 131.1, 129.9, 128.3, 127.3, 118.5, 113.6, 70.1, 55.4, 28.5; IR (ATR): 3085, 3057, 3001, 2954, 2927, 2868, 2836, 1708, 1629, 1608, 1509, 1462, 1445, 1295, 1249, 1182, 1161, 1033, 928, 827  $\text{cm}^{-1}$ ; HRMS(ESI)  $m/z$ :  $[\text{M}+\text{Na}]^+$  Calcd for  $\text{C}_{18}\text{H}_{18}\text{NaO}_2$  289.3298, found: 289.3293; Compound was obtained as *racemic*.


### (*R*,*E*)-4-hydroxy-4-(4-methoxyphenyl)-3-phenylpent-2-en-1-yl 2,2,2-trichloroacetimidate (**4e**)

  
**4e**  
( $R^L = 4\text{-MeOC}_6\text{H}_4$ ) 11% yield (4.7 mg); colorless oil;  $[\alpha]_{\text{D}}^{25} -67.5$  ( $c$  0.98,  $\text{CHCl}_3$ , 67% ee);  $R_f = 0.30$  (Hexane/EtOAc = 4/1);  $^1\text{H NMR}$  (600 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.20 (s, 1H), 7.34 (td,  $J = 5.8, 3.7$  Hz, 2H), 7.24-7.18 (m, 3H), 6.85 (td,  $J = 6.0, 3.7$  Hz, 2H), 6.77-6.75 (m, 2H), 6.28 (t,  $J = 6.9$  Hz, 1H), 4.55 (d,  $J = 6.9$  Hz, 2H), 3.82 (s, 3H), 1.95 (s, 1H), 1.69 (s, 3H);  $^{13}\text{C NMR}$  (151 MHz,  $\text{CDCl}_3$ ):  $\delta$  162.7, 158.8, 152.5, 137.5, 136.7, 129.5, 128.1, 127.7, 127.3, 120.1, 113.5, 91.5, 76.7, 67.3, 55.4, 28.8; IR (ATR): 3337, 2935, 2636, 2310, 1725, 1661, 1249, 1086, 772  $\text{cm}^{-1}$ ; HRMS(ESI)  $m/z$ :  $[\text{M}+\text{Na}]^+$  Calcd for  $\text{C}_{20}\text{H}_{20}\text{Cl}_3\text{NNaO}_3$  450.0401, found: 450.0401.; HPLC analysis: Chiralpak IA-3 column (Hexane:*i*PrOH = 95:5, 1.0 mL/min, 40 °C, 220 nm) 14.2 min (major), 17.7 min (minor). The absolute configurations were assigned as (*R*) by analogy with compound **4a**.


**(2*S*,3*R*)-2-(3-chlorophenyl)-2-methyl-3-phenyl-3-vinyloxirane (5f)**

  
40% yield (10.8 mg); colorless oil;  $[\alpha]_D^{27} +80.1$  (*c* 0.56, CHCl<sub>3</sub>, 95% ee);  $R_f = 0.33$  (Hexane/EtOAc= 10/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  7.14 (d, *J* = 1.4 Hz, 1H), 7.11 (d, *J* = 4.1 Hz, 4H), 7.05 (q, *J* = 4.4 Hz, 1H), 7.00-6.98 (m, 3H), 6.26 (dd, *J* = 17.2, 11.0 Hz, 1H), 5.41-5.32 (m, 2H), 1.77 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  142.6, 137.1, 135.8, 133.6, 128.9, 127.7, 127.4, 127.1, 127.0, 126.7, 124.6, 119.4, 71.6, 68.8, 20.2; IR (ATR): 2957, 2923, 2869, 1733, 1459, 1261, 1081, 772 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>17</sub>H<sub>15</sub>ClNaO 293.0704, found: 293.0703.; HPLC analysis: Chiralcel OD-3 column (Hexane:<sup>i</sup>PrOH = 99.9/0.1, 1.0 mL/min, 40 °C, 220 nm) 9.3 min (minor), 11.8 min (major). Configuration Assignment: The relative and absolute configurations were assigned as (2*S*,3*R*) by analogy with compound **5b**.


**(*R,E*)-4-(3-chlorophenyl)-4-hydroxy-3-phenylpent-2-en-1-yl 2,2,2-trichloroacetimidate (4f)**

  
45% yield (19.5 mg); colorless oil;  $[\alpha]_D^{21} -49.1$  (*c* 1.7, CHCl<sub>3</sub>, 85% ee);  $R_f = 0.34$  (Hexane/EtOAc= 4/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  8.23 (s, 1H), 7.44 (s, 1H), 7.29 (qd, *J* = 4.4, 2.2 Hz, 1H), 7.26-7.21 (m, 5H), 6.79 (dd, *J* = 8.2, 1.4 Hz, 2H), 6.26 (t, *J* = 6.5 Hz, 1H), 4.57 (q, *J* = 3.4 Hz, 2H), 2.01 (s, 1H), 1.71 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  162.6, 151.6, 147.7, 136.1, 134.2, 129.5, 129.4, 128.2, 127.9, 127.4, 126.3, 124.2, 121.2, 91.5, 76.7, 67.1, 28.9; IR (ATR): 3339, 2980, 2310, 1725, 1661, 1076, 795, 703 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>19</sub>H<sub>17</sub>Cl<sub>4</sub>NNaO<sub>2</sub> 453.9906, found: 453.9905.; HPLC analysis: Chiralpak IA-3 column (Hexane:<sup>i</sup>PrOH = 98:2, 1.0 mL/min, 40 °C, 220 nm) 18.5 min (minor), 19.4 min (major). The absolute configurations were assigned as (*R*) by analogy with compound **4a**.

**(2*S*,3*R*)-2-methyl-3-phenyl-2-(*m*-tolyl)-3-vinyloxirane (5g)**


  
41% yield (10.3 mg); colorless oil;  $[\alpha]_D^{27} +126.1$  (*c* 0.5, CHCl<sub>3</sub>, 94% ee);  $R_f = 0.44$  (Hexane/EtOAc= 10/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  7.13-7.07 (m, 4H), 7.03-7.01 (m, 1H), 6.97-6.91 (m, 3H), 6.82 (d, *J* = 7.6 Hz, 1H), 6.29 (dd, *J* = 17.2, 10.3 Hz, 1H), 5.39-5.31 (m, 2H), 2.17 (s, 3H), 1.77 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  140.3, 137.6, 137.1, 136.3, 127.5, 127.5, 127.1, 126.8, 123.5, 118.9, 71.5, 69.5, 21.4, 20.5; IR (ATR): 2953, 2922, 2868, 2852, 1734, 1459, 1376, 772 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>18</sub>H<sub>18</sub>NaO 273.1250, found: 273.1249.; HPLC analysis: Chiralcel OD-3 column (Hexane:<sup>i</sup>PrOH = 99.5/0.5, 1.0 mL/min, 40 °C, 220 nm) 5.2 min (minor), 5.7 min (major). Configuration Assignment: The relative and absolute configurations were assigned as (2*S*,3*R*) by analogy with compound **5b**.

**(*R,E*)-4-hydroxy-3-phenyl-4-(*m*-tolyl)pent-2-en-1-yl 2,2,2-trichloroacetimidate (4g)**


  
43% yield (17.7 mg); colorless oil;  $[\alpha]_D^{25} -59.1$  (*c* 1.72, CHCl<sub>3</sub>, 78% ee);  $R_f = 0.35$  (Hexane/EtOAc= 4/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  8.19 (s, 1H), 7.25 (s, 1H), 7.24-7.17 (m, 5H), 7.09-7.07 (m, 1H), 6.77 (dt, *J* = 8.2, 1.7 Hz, 2H), 6.27 (t, *J* = 6.5 Hz, 1H), 4.56 (dd, *J* = 6.9, 1.4 Hz, 2H), 2.34 (s, 3H), 2.06 (s, 1H), 1.70 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  162.6, 152.4, 145.4, 137.8, 136.5, 129.5, 128.1, 128.1, 127.7, 126.6, 123.0, 120.4, 91.5, 76.9, 67.3, 28.9, 21.7; IR (ATR): 3341, 2954, 2923, 1661, 1294, 1077, 976, 821, 794, 704, 648 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>20</sub>Cl<sub>3</sub>NNaO<sub>2</sub> 434.0452, found: 434.0451.; HPLC

analysis: Chiralpak IA-3 column (Hexane:*i*PrOH = 95:5, 1.0 mL/min, 40 °C, 220 nm) 8.7 min (minor), 9.7 min (major). The absolute configurations were assigned as (*R*) by analogy with compound **4a**.


**(2*S*,3*R*)-2-(3-methoxyphenyl)-2-methyl-3-phenyl-3-vinyloxirane (5h)**

 45% yield (10.9 mg); colorless oil;  $[\alpha]_D^{27} +120.5$  (*c* 0.8, CHCl<sub>3</sub>, 90% ee);  $R_f = 0.67$  (Hexane/EtOAc= 4/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 7.14-7.12 (m, 2H), 7.10-7.08 (m, 2H), 7.05-6.99 (m, 2H), 6.76-6.75 (m, 1H), 6.66 (q, *J* = 1.4 Hz, 1H), 6.57-6.55 (m, 1H), 6.28 (dd, *J* = 17.2, 10.3 Hz, 1H), 5.39-5.31 (m, 2H), 3.63 (s, 3H), 1.78 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 158.9, 142.1, 137.5, 136.2, 128.6, 127.6, 127.5, 126.9, 119.0, 118.9, 112.7, 111.9, 71.6, 69.3, 55.2, 20.4; IR (ATR): 2954, 2923, 2852, 1734, 1602, 1454, 1287, 1216, 1046, 772, 699 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>18</sub>H<sub>18</sub>NaO<sub>2</sub> 289.1199, found: 289.1199; HPLC analysis: Chiralcel OD-3 column (Hexane:*i*PrOH = 99.5:0.5, 1.0 mL/min, 40 °C, 220 nm) 6.8 min (minor), 7.2 min (major). Configuration Assignment: The relative and absolute configurations were assigned as (*2S,3R*) by analogy with compound **5a**.


**(*R,E*)-4-hydroxy-4-(3-methoxyphenyl)-3-phenylpent-2-en-1-yl 2,2,2-trichloroacetimidate (4h)**

 37% yield (15.9 mg); colorless oil;  $[\alpha]_D^{25} -10.2$  (*c* 1.38, CHCl<sub>3</sub>, 94% ee);  $R_f = 0.30$  (Hexane/EtOAc= 4/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 8.20 (s, 1H), 7.26-7.18 (m, 4H), 7.01-6.99 (m, 2H), 6.82-6.78 (m, 3H), 6.27 (t, *J* = 6.5 Hz, 1H), 4.56 (dd, *J* = 6.9, 1.4 Hz, 2H), 3.78 (s, 3H), 2.10 (s, 1H), 1.71 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): 162.6, 159.6, 152.12, 147.3, 136.4, 129.5, 129.2, 128.1, 127.8, 120.5, 118.4, 112.6, 111.8, 91.5, 76.9, 67.2, 55.4, 28.9; IR (ATR): 3338, 2938, 1661, 1598, 1486, 1288, 1252, 1074, 976, 794, 774, 703, 647 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>20</sub>Cl<sub>3</sub>NNaO<sub>3</sub> 450.0401, found: 450.0400; HPLC analysis: Chiralcel OD-3 column (Hexane:*i*PrOH = 95/5, 40 °C, 220 nm) 11.4 min (major), 14.2 min (minor). The absolute configurations were assigned as (*R*) by analogy with compound **4a**.

**(2*S*,3*R*)-2-(2-chlorophenyl)-2-methyl-3-phenyl-3-vinyloxirane (5i)**


 37% yield (10.3 mg); colorless oil;  $[\alpha]_D^{25} +140.2$  (*c* 0.1, CHCl<sub>3</sub>, 94% ee);  $R_f = 0.32$  (Hexane/EtOAc= 10/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 7.45 (dd, *J* = 7.9, 1.7 Hz, 1H), 7.30-7.28 (m, 2H), 7.10-7.06 (m, 3H), 7.04-6.97 (m, 3H), 6.44 (dd, *J* = 17.2, 11.0 Hz, 1H), 5.48-5.45 (m, 2H), 1.76 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 138.7, 136.9, 134.7, 131.2, 128.9, 128.9, 128.5, 127.2, 127.0, 126.8, 126.3, 119.0, 70.7, 70.1, 19.4; IR (ATR): 2955, 2925, 2854, 1733, 1446, 731, 699 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>17</sub>H<sub>15</sub>ClNaO: 293.0704, found: 293.0703.; HPLC analysis: Chiralcel OD-3 column (Hexane:*i*PrOH = 99.5:0.5, 1.0 mL/min, 40 °C, 220 nm) 5.0 min (minor), 5.4 min (major). Configuration Assignment: The relative and absolute configurations were assigned as (*2S,3R*) by analogy with compound **5b**.

**(*S,E*)-4-(2-chlorophenyl)-4-hydroxy-3-phenylpent-2-en-1-yl 2,2,2-trichloroacetimidate (4i)**


 49% yield (20.0 mg); colorless oil;  $[\alpha]_D^{25} -1.7$  (*c* 1.01, CHCl<sub>3</sub>, 56% ee);  $R_f = 0.34$  (Hexane/EtOAc= 4/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 8.17 (s, 1H), 7.50 (dd, *J* = 7.2, 2.4 Hz, 1H), 7.36 (dd, *J* = 7.2, 1.7 Hz, 1H), 7.23 (q, *J* = 3.4 Hz, 3H), 7.21-7.17 (m, 2H), 7.03 (q, *J* = 3.0 Hz, 2H), 6.05 (t, *J* = 6.9 Hz, 1H), 4.56 (d, *J* = 6.9 Hz, 2H), 3.04 (s, 1H), 1.79 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 162.6, 150.5, 142.2, 136.5, 132.3, 131.3, 129.5, 128.9, 128.4, 128.0, 127.7, 126.9, 122.1, 91.5, 76.9, 67.1, 27.3; IR (ATR): 3340,

2954, 2925, 1661, 1293, 1219, 1078, 796, 702  $\text{cm}^{-1}$ ; HRMS(ESI)  $m/z$ :  $[M+Na]^+$  Calcd for  $\text{C}_{19}\text{H}_{17}\text{Cl}_4\text{NNaO}_2$  453.9906, found.: 453.9905; HPLC analysis: Chiralpak IA-3 column (Hexane: $i$ PrOH = 95:5, 1.0 mL/min, 40  $^\circ\text{C}$ , 220 nm) 10.8 min (minor), 12.3 min (major). The absolute configurations were assigned as (*R*) by analogy with compound **4a**.


**(2*S*,3*R*)-2-isopropyl-2-methyl-3-phenyl-3-vinyloxirane (5j)**

 32% yield (7.9 mg); colorless oil;  $[\alpha]_{\text{D}}^{27} +74.4$  (*c* 0.1,  $\text{CHCl}_3$ , 92% ee);  $R_f = 0.72$  (Hexane/EtOAc = 4/1);  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.36-7.32 (m, 4H), 7.27-7.25 (m, 2H), 6.18 (dd,  $J = 17.2, 11.0$  Hz, 1H), 5.28-5.20 (m, 2H), 1.28 (s, 3H), 1.17-1.12 (m, 1H), 0.96 (d,  $J = 6.9$  Hz, 3H), 0.74 (d,  $J = 6.9$  Hz, 3H);  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ):  $\delta$  138.7, 136.7, 128.1, 127.1, 127.1, 117.9, 71.8, 71.3, 31.4, 17.9, 17.8, 11.7; IR (ATR): 2953, 2922, 2868, 2853, 1734, 1460, 1376, 772  $\text{cm}^{-1}$ ; HRMS(ESI)  $m/z$ :  $[M+Na]^+$  Calcd for  $\text{C}_{14}\text{H}_{18}\text{NaO}$  225.1250, found: 225.1249.; HPLC analysis: Chiralpak IC-3 column (Hexane = 100, 1.0 mL/min, 40  $^\circ\text{C}$ , 220 nm) 10.0 min (minor), 11.6 min (major). Configuration Assignment: The relative and absolute configurations were assigned as (*2S,3R*) by analogy with compound **5b**.


**(*R,E*)-4-hydroxy-4,5-dimethyl-3-phenylhex-2-en-1-yl 2,2,2-trichloroacetimidate (4j)**

 52% yield (18.2 mg); colorless oil;  $[\alpha]_{\text{D}}^{25} +7.5$  (*c* 1.69,  $\text{CHCl}_3$ , 50% ee);  $R_f = 0.34$  (Hexane/EtOAc = 10/1);  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.17 (s, 1H), 7.35-7.29 (m, 3H), 7.16 (q,  $J = 2.7$  Hz, 2H), 6.09 (t,  $J = 6.5$  Hz, 1H), 4.49 (d,  $J = 6.2$  Hz, 2H), 1.79-1.74 (m, 1H), 1.41 (s, 1H), 1.33 (s, 3H), 0.97 (d,  $J = 6.9$  Hz, 3H), 0.93 (d,  $J = 6.2$  Hz, 3H);  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ):  $\delta$  162.6, 152.8, 137.5, 129.4, 128.3, 127.5, 120.5, 91.6, 76.9, 67.3, 33.9, 24.2, 17.1, 17.1; IR (ATR): 3343, 2972, 2876, 1724, 1661, 1370, 1296, 1219, 1075, 977, 772, 707  $\text{cm}^{-1}$ ; HRMS(ESI)  $m/z$ :  $[M+Na]^+$  Calcd for  $\text{C}_{16}\text{H}_{20}\text{Cl}_3\text{NNaO}_2$  386.0452, found: 386.0452; HPLC analysis: Chiralpak IA-3 column (Hexane: $i$ PrOH = 95:5, 1.0 mL/min, 40  $^\circ\text{C}$ , 220 nm) 6.6 min (major), 7.1 min (minor). The absolute configurations were assigned as (*R*) by analogy with compound **4a**.

**(2*S*,3*R*)-2-ethyl-2,3-diphenyl-3-vinyloxirane (5k)**

 49% yield (12.3 mg); colorless oil;  $[\alpha]_{\text{D}}^{27} +15.0$  (*c* 0.98,  $\text{CHCl}_3$ , 95% ee);  $R_f = 0.73$  (Hexane/EtOAc = 4/1);  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ):  $\delta$  7.12-7.11 (m, 4H), 7.07 (td,  $J = 7.6, 3.7$  Hz, 4H), 7.02-6.99 (m, 2H), 6.35 (dd,  $J = 17.2, 11.0$  Hz, 1H), 5.39-5.36 (m, 2H), 2.16 (td,  $J = 14.4, 7.1$  Hz, 1H), 2.01 (td,  $J = 14.3, 7.1$  Hz, 1H), 0.93 (t,  $J = 7.6$  Hz, 3H);  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ):  $\delta$  138.4, 138.0, 135.9, 129.9, 127.5, 127.5, 127.2, 127.2, 126.7, 126.7, 118.6, 73.9, 71.8, 26.0, 9.5; IR (ATR): 2954, 2922, 2852, 1732, 1461, 1376, 1217, 759, 698  $\text{cm}^{-1}$ ; HRMS(ESI)  $m/z$ :  $[M+Na]^+$  Calcd for  $\text{C}_{18}\text{H}_{18}\text{NaO}$  273.1250, found: 273.1249.; HPLC analysis: Chiralcel OD-3 column (Hexane: $i$ PrOH = 99.5/0.5, 1.0 mL/min, 40  $^\circ\text{C}$ , 220 nm) 4.6 min (minor), 5.1 min (major). Configuration Assignment: The relative and absolute configurations were assigned as (*2S,3R*) by analogy with compound **5b**.


**(*R,E*)-4-hydroxy-3,4-diphenylhex-2-en-1-yl 2,2,2-trichloroacetimidate (4k)**

 39% yield (16.1 mg); colorless oil;  $[\alpha]_{\text{D}}^{25} -16.7$  (*c* 1.48,  $\text{CHCl}_3$ , 98% ee);  $R_f = 0.32$  (Hexane/EtOAc = 10/1);  $^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ):  $\delta$  8.20 (s, 1H), 7.38-7.36 (m, 2H), 7.31 (t,  $J = 7.6$  Hz, 2H), 7.27-7.21 (m, 2H), 7.17 (t,  $J = 7.6$  Hz, 2H), 6.71 (d,  $J = 6.9$  Hz, 2H), 6.27 (t,  $J = 6.5$  Hz, 1H), 4.55 (d,  $J = 6.9$  Hz, 2H), 2.06 (td,  $J = 7.9, 6.6$  Hz, 2H), 1.91 (d,  $J = 2.1$  Hz, 1H), 0.92 (t,  $J = 7.2$  Hz, 3H);  $^{13}\text{C}$  NMR (151




MHz, CDCl<sub>3</sub>):  $\delta$  162.6, 151.4, 144.3, 136.5, 129.5, 128.1, 128.1, 127.7, 127.2, 126.5, 120.8, 91.5, 79.2, 67.3, 32.4, 7.9; IR (ATR): 3340, 2955, 2925, 1661, 1291, 1076, 976, 795, 771, 700, 648 cm<sup>-1</sup>; HRMS(ESI)  $m/z$ : [M+Na]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>20</sub>Cl<sub>3</sub>NNaO<sub>2</sub> 434.0452, found: 434.0452.; HPLC analysis: Chiralpak IA-3 column (Hexane:<sup>i</sup>PrOH = 95:5, 1.0 mL/min, 40 °C, 220 nm) 8.1 min (minor), 9.0 min (major). Configuration Assignment: The absolute configurations were assigned as (*R*) by analogy with compound **4a**.


**(2*R*,3*S*)-2-(4-methoxyphenyl)-3-methyl-3-phenyl-2-vinyloxirane (5l)**

 44% yield (11.7 mg); colorless oil; [ $\alpha$ ]<sub>D</sub><sup>26</sup> +266.3 (*c* 0.3, CHCl<sub>3</sub>, 86% ee);  $R_f$  = 0.68 (Hexane/EtOAc= 4/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  7.14-7.13 (m, 2H), 7.10-7.08 (m, 2H), 7.02 (qd, *J* = 6.0, 4.0 Hz, 3H), 6.61 (Ar = 4-MeOC<sub>6</sub>H<sub>4</sub>) (td, *J* = 5.8, 3.4 Hz, 2H), 6.27 (dd, *J* = 16.8, 10.7 Hz, 1H), 5.37-5.28 (m, 2H), 3.67 (s, 3H), 1.78 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  158.3, 140.6, 136.6, 129.8, 128.6, 127.6, 126.7, 126.4, 118.7, 113.0, 71.2, 69.4, 55.2, 20.5; IR (ATR): 2956, 2922, 2869, 1741, 1460, 1247, 1026, 804, 769 cm<sup>-1</sup>; HRMS(ESI)  $m/z$ : [M+Na]<sup>+</sup> Calcd for C<sub>18</sub>H<sub>18</sub>NaO<sub>2</sub> 289.1199, found: 289.1198; HPLC analysis Chiralcel OD-3 column (Hexane:<sup>i</sup>PrOH = 99.5/0.5, 1.0 mL/min, 40 °C, 220 nm) 7.2 min (minor), 7.4 min (major). Configuration Assignment: The relative and absolute configurations were assigned as (2*R*,3*S*) by analogy with compound **5b**.


**(*R,E*)-4-hydroxy-3-(4-methoxyphenyl)-4-phenylpent-2-en-1-yl 2,2,2-trichloroacetimidate (4l)**

 36% yield (15.4 mg); colorless oil; [ $\alpha$ ]<sub>D</sub><sup>25</sup> -29.5 (*c* 1.15, CHCl<sub>3</sub>, 84% ee);  $R_f$  = 0.30 (Hexane/EtOAc= 4/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  8.20 (s, 1H), 7.43-7.42 (m, 2H), 7.33-7.30 (m, 2H), 7.25-7.27 (m, 1H), 6.72 (td, *J* = 5.5, 3.2 Hz, 2H), 6.68-6.66 (m, 2H), 6.27 (t, *J* = 6.9 Hz, 1H), 4.58 (d, *J* = 6.2 Hz, 2H), 3.76-3.74 (m, 3H), 2.05 (s, 1H), 1.71 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  162.7, 159.2, 152.0, 145.6, 130.7, 128.5, 128.2, 127.3, 125.9, 120.6, 113.6, 91.6, 67.4, 55.3, 28.9; IR (ATR): 3337, 2935, 2636, 2310, 1725, 1661, 1249, 1086, 772 cm<sup>-1</sup>; HRMS(ESI)  $m/z$ : [M+Na]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>20</sub>Cl<sub>3</sub>NNaO<sub>3</sub> 450.0401, found: 450.040; HPLC analysis: Chiralpak IA-3 column (Hexane:<sup>i</sup>PrOH = 95/5, 1.0 mL/min, 40 °C, 220 nm) 12.1 min (minor), 14.7 min (major). The absolute configurations were assigned as (*R*) by analogy with compound **4a**.

**(2*R*,3*S*)-2-(4-chlorophenyl)-3-methyl-3-phenyl-2-vinyloxirane (5m)**


 34% yield (13.3 mg); colorless oil; [ $\alpha$ ]<sub>D</sub><sup>26</sup> +123.8 (*c* 1.54, CHCl<sub>3</sub>, 92% ee);  $R_f$  = 0.32 (Hexane/EtOAc= 10/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  7.13-7.08 (m, 4H), 7.06-7.03 (m, 5H), 6.25 (dd, *J* = 17.2, 10.3 Hz, 1H), 5.40 (dd, *J* = 11.0, 1.4 Hz, 1H), 5.31 (dd, *J* = 16.8, 1.7 Hz, 1H), 1.78 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  140.1, 136.3, 135.7, 132.6, 128.9, 127.85, 127.82, 127.0, 126.3, 119.4, 70.9, 69.6, 20.5; IR (ATR): 2958, 2922, 2869, 1741, 1459, 1260, 1092, 1023, 802, 772 cm<sup>-1</sup>; HRMS(ESI)  $m/z$ : [M+Na]<sup>+</sup> Calcd for C<sub>17</sub>H<sub>15</sub>ClNaO 293.0704, found: 293.0703; HPLC analysis: Chiralcel OD-3 column (Hexane:<sup>i</sup>PrOH = 99.5/0.5, 1.0 mL/min, 40 °C, 220 nm) 4.8 min (major), 5.1 min (minor). Configuration Assignment: The relative and absolute configurations were assigned as (2*R*,3*S*) by analogy with compound **5b**.

**(*R,E*)-3-(4-chlorophenyl)-4-hydroxy-4-phenylpent-2-en-1-yl 2,2,2-trichloroacetimidate (4m)**




49% yield (14.7 mg); colorless oil;  $[\alpha]_D^{25}$  -7.1 (*c* 3.37, CHCl<sub>3</sub>, 56% ee);  $R_f$  = 0.34 (Hexane/EtOAc= 4/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 8.22 (s, 1H), 7.40-7.38 (m, 2H), 7.33-7.31 (m, 2H), 7.28-7.26 (m, 1H), 7.16 (dt, *J* = 8.9, 2.1 Hz, 2H), 6.68 (dd, *J* = 8.6, 2.4 Hz, 2H), 6.32 (t, *J* = 6.9 Hz, 1H), 4.54 (d, *J* = 6.9 Hz, 2H), 2.03 (s, 1H), 1.71 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 162.6, 151.4, 144.9, 135.1, 133.8, 130.9, 128.4, 128.3, 127.5, 125.9, 120.8, 91.5, 76.9, 66.9, 28.7; IR (ATR): 3338, 2983, 1660, 1489, 1090, 829, 768, 701 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>19</sub>H<sub>17</sub>Cl<sub>4</sub>NNaO 453.9906, found: 453.9905; HPLC analysis: Chiralpak IA-3 column (Hexane:<sup>i</sup>PrOH = 95/5, 1.0 mL/min, 40 °C, 220 nm) 10.2 min (minor), 11.8 min (major). The absolute configurations were assigned as (*R*) by analogy with compound **4a**.

**(2*R*,3*S*)-2-([1,1'-biphenyl]-4-yl)-3-methyl-3-phenyl-2-vinyloxirane (5n)**




26% yield (11.9 mg); colorless oil;  $[\alpha]_D^{26}$  +164.1 (*c* 1.56, CHCl<sub>3</sub>, 95% ee);  $R_f$  = 0.73 (Hexane/EtOAc= 4/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 7.47-7.45 (m, 2H), 7.37-7.35 (m, 2H), 7.33-7.31 (m, 2H), 7.29-7.26 (m, 1H), 7.19-7.16 (m, 4H), 7.10-7.07 (m, 2H), 7.01 (dd, *J* = 8.2, 6.2 Hz, 1H), 6.33 (dd, *J* = 16.8, 10.7 Hz, 1H), 5.42-5.36 (m, 2H), 1.80 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 140.7, 140.4, 139.5, 136.7, 136.2, 128.7, 127.8, 127.7, 127.3, 127.0, 126.8, 126.4, 126.3, 119.0, 71.4, 69.6, 20.5; IR (ATR): 3028, 2957, 2924, 2868, 1740, 1487, 1446, 768, 698 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>23</sub>H<sub>20</sub>NaO 335.1406, found: 335.1406; HPLC analysis: Chiralcel OD-3 column (Hexane:<sup>i</sup>PrOH = 99.9/0.1, 1.0 mL/min, 40 °C, 220 nm) 12.8 min (minor), 13.2 min (major). Configuration Assignment: The relative and absolute configurations were assigned as (2*R*,3*S*) by analogy with compound **5b**.

**(*R,E*)-3-([1,1'-biphenyl]-4-yl)-4-hydroxy-4-phenylpent-2-en-1-yl 2,2,2-trichloroacetimidate (4n)**




71% yield (23.3 mg); colorless oil;  $[\alpha]_D^{25}$  -27.2 (*c* 5.6, CHCl<sub>3</sub>, 36% ee);  $R_f$  = 0.33 (Hexane/EtOAc= 10/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 8.23 (s, 1H), 7.54 (d, *J* = 8.2 Hz, 2H), 7.47-7.46 (m, 2H), 7.43-7.40 (m, 4H), 7.36-7.27 (m, 4H), 6.84-6.82 (m, 2H), 6.32 (t, *J* = 6.9 Hz, 1H), 4.63 (d, *J* = 6.9 Hz, 2H), 2.05 (s, 1H), 1.76 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 162.7, 152.0, 145.5, 140.5, 140.5, 135.5, 130.0, 128.9, 128.3, 127.5, 127.4, 127.1, 126.7, 126.0, 120.6, 91.5, 67.3, 29.0; IR (ATR, cm<sup>-1</sup>): 3337, 2983, 1661, 1486, 1300, 1074, 771, 699; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>25</sub>H<sub>22</sub>Cl<sub>3</sub>NNaO<sub>2</sub> 496.0608, found: 496.0607; HPLC analysis: Chiralpak IA-3 column (Hexane:<sup>i</sup>PrOH = 95/5, 1.0 mL/min, 40 °C, 220 nm) 13.6 min (minor), 15.4 min (major). The absolute configurations were assigned as (*R*) by analogy with compound **4a**.

**(2*S*,3*R*)-2-methyl-2-phenyl-3-(*m*-tolyl)-3-vinyloxirane (5p)**



30% yield (7.5 mg); colorless oil;  $[\alpha]_D^{26}$  +120.7 (*c* 1.1, CHCl<sub>3</sub>, 96% ee);  $R_f$  = 0.44 (Hexane/EtOAc= 10/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 7.14-7.13 (m, 2H), 7.09-7.06 (m, 2H), 7.03-7.02 (m, 1H), 6.96-6.93 (m, 2H), 6.88 (d, *J* = 7.9 Hz, 1H), 6.82 (d, *J* = 7.2 Hz, 1H), 6.29 (dd, *J* = 17.2, 10.7 Hz, 1H), 5.38-5.32 (m, 2H), 2.17 (s, 3H), 1.78 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 140.5, 137.5, 137.1, 136.4, 128.2, 127.5, 127.4, 126.7, 126.4, 124.5, 118.7, 71.5, 69.4, 21.4, 20.5; IR (ATR): 2954, 2922, 2868, 2853, 1741, 1460, 1376, 1081, 804, 770 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>18</sub>H<sub>18</sub>NaO: 273.1250, found: 273.1249; HPLC analysis: Chiralcel OD-3 column (Hexane:<sup>i</sup>PrOH = 99.5/0.5, 1.0 mL/min, 40 °C, 220 nm) 4.9 min (minor), 5.1 min (major). Configuration Assignment: The relative and absolute configurations were assigned as (2*S*,3*R*) by analogy with compound **5b**.

**(*R,E*)-4-hydroxy-4-phenyl-3-(*m*-tolyl)pent-2-en-1-yl 2,2,2-trichloroacetimidate (4p)**




63% yield (26.0 mg); colorless oil;  $[\alpha]_{\text{D}}^{25} -118.9$  (*c* 1.35, CHCl<sub>3</sub>, 56% ee);  $R_f = 0.35$  (Hexane/EtOAc= 4/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  8.20 (s, 1H), 7.43 (d, *J* = 7.6 Hz, 2H), 7.32 (t, *J* = 7.6 Hz, 2H), 7.28-7.25 (m, 1H), 7.07-7.02 (m, 2H), 6.59 (s, 1H), 6.52 (d, *J* = 6.9 Hz, 1H), 6.24 (t, *J* = 6.5 Hz, 1H), 4.56 (d, *J* = 7.6 Hz, 2H), 2.21 (s, 3H), 2.03 (s, 1H), 1.72 (s, 3H); <sup>13</sup>C NMR (151

MHz, CDCl<sub>3</sub>):  $\delta$  162.7, 152.5, 145.6, 137.6, 136.3, 130.4, 128.5, 128.2, 127.9, 127.3, 126.5, 126.0, 120.3, 91.7, 76.95, 67.3, 28.9, 21.5; IR (ATR): 3338, 2973, 1607, 1509, 1287, 1244, 1074, 796, 701, 648 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>20</sub>H<sub>20</sub>Cl<sub>3</sub>NNaO<sub>2</sub> 434.0452, found: 434.0452; HPLC analysis: Chiralpak IA-3 column (Hexane:<sup>i</sup>PrOH = 95/5, 1.0 mL/min, 40 °C, 220 nm) 8.3 min (minor), 9.5 min (major). The absolute configurations were assigned as (*R*) by analogy with compound

4a.


**(2*R*,3*S*)-2-(3-chlorophenyl)-3-methyl-3-phenyl-2-vinyloxirane (5q)**



30% yield (8.1 mg); colorless oil;  $[\alpha]_{\text{D}}^{25} +131.0$  (*c* 0.3, CHCl<sub>3</sub>, 97% ee);  $R_f = 0.33$  (Hexane/EtOAc= 10/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  7.14-7.09 (m, 5H), 7.06-7.03 (m, 1H), 6.99 (qd, *J* = 3.7, 2.1 Hz, 3H), 6.26 (dd, *J* = 17.2, 11.0 Hz, 1H), 5.43-5.33 (m, 2H), 1.77 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  139.9, 139.7,

135.4, 133.5, 128.9, 127.7, 127.7, 127.1, 127.1, 126.3, 125.6, 119.5, 71.2, 69.7, 20.4; IR (ATR): 2953, 2919, 2868, 2850, 1741, 1460, 1376, 772 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>17</sub>H<sub>15</sub>ClNaO 293.0704, found: 293.0703; HPLC analysis: Chiralcel OD-3 column (Hexane:<sup>i</sup>PrOH = 99.9:0.1, 1.0 mL/min, 40 °C, 220 nm) 11.0 min (minor), 12.0 min (major). Configuration Assignment: The relative and absolute configurations were assigned as (2*R*,3*S*) by analogy with compound 5b.


**(*R,E*)-3-(3-chlorophenyl)-4-hydroxy-4-phenylpent-2-en-1-yl 2,2,2-trichloroacetimidate (4q)**



51% yield (21.7 mg); colorless oil;  $[\alpha]_{\text{D}}^{25} -76.4$  (*c* 2.04, CHCl<sub>3</sub>, 47% ee);  $R_f = 0.33$  (Hexane/EtOAc= 4/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  8.23 (s, 1H), 7.41-7.39 (m, 2H), 7.35-7.32 (m, 2H), 7.30-7.27 (m, 1H), 7.22-7.20 (m, 1H), 7.11 (t, *J* = 7.9 Hz, 1H), 6.78 (t, *J* = 2.1 Hz, 1H), 6.62-6.61 (m, 1H), 6.30 (t, *J* = 6.9 Hz, 1H), 4.54 (d, *J* = 6.9 Hz, 2H), 2.00 (t, *J* = 2.1 Hz, 1H), 1.72

(s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  162.6, 151.3, 144.8, 138.5, 133.9, 129.7, 129.3, 128.4, 127.9, 127.7, 127.5, 125.9, 121.0, 91.5, 76.8, 66.8, 28.7; IR (ATR): 3339, 1662, 1301, 1080, 771, 701, 649 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>19</sub>H<sub>17</sub>Cl<sub>3</sub>NNaO<sub>2</sub> 453.9906, found: 453.9905; HPLC analysis: Chiralpak IA-3 column (Hexane:<sup>i</sup>PrOH = 95:5, 1.0 mL/min, 40 °C, 220 nm) 10.3 min (minor), 11.2 min (major). The absolute configurations were assigned as (*R*) by analogy with compound 4a.

**(2*S*,3*R*)-2-methyl-3-(naphthalen-2-yl)-2-phenyl-3-vinyloxirane (5s)**




53% yield (13.2 mg); colorless oil;  $[\alpha]_{\text{D}}^{25} +124.5$  (*c* 0.79, CHCl<sub>3</sub>, 84% ee);  $R_f = 0.72$  (Hexane/EtOAc= 4/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  7.68-7.65 (m, 2H), 7.61 (s, 1H), 7.55 (d, *J* = 8.2 Hz, 1H), 7.38-7.33 (m, 2H), 7.24-7.23 (m, 1H), 7.19-7.17 (m, 2H), 7.02-6.99 (m, 2H), 6.93-6.90 (m, 1H), 6.36 (dd, *J* = 17.2,


11.0 Hz, 1H), 5.41-5.33 (m, 2H), 1.84 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  140.4, 136.3, 135.2, 132.8, 132.4, 127.9, 127.6, 127.2, 126.8, 126.6, 126.3, 125.9, 125.7, 125.5, 119.3, 71.6, 69.7, 20.6; IR (ATR): 2954, 2922, 2868, 2852, 1741, 1460, 1376, 1219, 772 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>21</sub>H<sub>18</sub>NaO 309.1250, found: 309.1249; HPLC analysis:

Chiralcel OD-3 column (Hexane:<sup>i</sup>PrOH = 99.8:0.2, 1.0 mL/min, 40 °C, 220 nm) 10.4 min (minor), 10.8 min (major). Configuration Assignment: The relative and absolute configurations were assigned as (2*S*,3*R*) by analogy with compound **5b**.


**(*R,E*)-4-hydroxy-3-(naphthalen-2-yl)-4-phenylpent-2-en-1-yl 2,2,2-trichloroacetimidate (4s)**

  
 (Ar = 2-naphthyl) 34% yield (18.8 mg); colorless oil;  $[\alpha]_D^{21} -23.1$  (c 3.3, CHCl<sub>3</sub>, >99% ee);  $R_f = 0.32$  (Hexane/EtOAc= 4/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 8.17 (s, 1H), 7.77-7.76 (m, 1H), 7.64 (d, *J* = 8.2 Hz, 2H), 7.46-7.41 (m, 4H), 7.33 (t, *J* = 7.6 Hz, 2H), 7.30-7.27 (m, 1H), 7.25 (d, *J* = 5.5 Hz, 1H), 6.84 (d, *J* = 8.2 Hz, 1H), 6.37 (t, *J* = 6.9 Hz, 1H), 4.58 (d, *J* = 6.9 Hz, 2H), 2.12-2.10 (m, 1H), 1.76 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 162.6, 152.4, 145.4, 134.1, 132.8, 132.7, 128.7, 128.3, 128.2, 127.7, 127.5, 127.4, 126.3, 126.3, 126.1, 120.8, 91.5, 67.2, 28.9; IR (ATR): 3335, 2981, 1660, 1297, 1073, 820, 796, 700, 648 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>23</sub>H<sub>20</sub>Cl<sub>3</sub>NNaO<sub>2</sub>: 470.0452, found:470.0451; HPLC analysis: Chiralpak IA-3 column (Hexane:<sup>i</sup>PrOH = 95/5, 1.0 mL/min, 40 °C, 220 nm) 13.8 min (minor), 15.1 min (major). The absolute configurations were assigned as (*R*) by analogy with compound **4a**.

**(2*S*,3*S*)-2-methyl-2-phenyl-3-(thiophen-2-yl)-3-vinyloxirane (5t)**


  
 (Ar = 2-thiophenyl) 40% yield (9.7 mg); colorless oil;  $[\alpha]_D^{26} +51.6$  (c 0.2, CHCl<sub>3</sub>, 86% ee (major diastereomer), 90% ee (minor diastereomer));  $R_f = 0.33$  (Hexane/EtOAc= 10/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) for mixture of diastereomers: δ 7.40-7.35 (m, 4H), 7.32-7.28 (m, 2H), 7.25-7.22 (m, 2H), 7.18 (t, *J* = 7.2 Hz, 2H), 7.13 (tt, *J* = 6.6 Hz, 1.2 Hz, 1H), 7.09-7.05 (m, 2H), 7.00-6.98 (m, 1H), 6.71-6.66 (m, 2H), 6.32 (dd, *J* = 16.8 Hz, 10.2 Hz, 1H), 5.53-5.44 (m, 3H), 5.19-5.11 (m, 2H), 1.74 (s, 3H), 1.49 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) for mixture of diastereomers: δ 141.3, 140.2, 136.0, 135.3, 128.3, 127.8, 127.5, 127.2, 126.8, 126.7, 126.6, 126.5, 126.22, 126.16, 125.1, 124.8, 120.5, 119.0, 71.2, 71.0, 68.3, 22.2, 21.1, some carbon could not be assigned due to presence of diastereomers; IR (ATR): 2955, 2922, 2869, 1741, 1436, 1376, 1219, 772 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>15</sub>H<sub>16</sub>NaOS 265.0658, Found: 265.0657; HPLC analysis: Chiralcel OD-3 column (Hexane:<sup>i</sup>PrOH = 99.8/0.2, 1.0 mL/min, 40 °C, 220 nm) major diastereomer: 9.8 min (minor), 11.8 min (major), minor diastereomer: 7.8 min (major), 8.8 min (minor). Configuration Assignment: The relative and absolute configurations were assigned as (2*S*,3*S*) by analogy with compound **5b**.

**(*R,Z*)-4-hydroxy-4-phenyl-3-(thiophen-2-yl)pent-2-en-1-yl 2,2,2-trichloroacetimidate (4t)**

  
 (Ar = 2-thiophenyl) 49% yield (19.8 mg); colorless oil;  $[\alpha]_D^{25} -6.84$  (c 1.35, CHCl<sub>3</sub>, 48% ee);  $R_f = 0.31$  (Hexane/EtOAc= 4/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>): δ 8.29 (s, 1H), 7.49-7.47 (m, 2H), 7.36-7.34 (m, 2H), 7.31-7.28 (m, 1H), 7.20-7.19 (m, 1H), 6.90 (q, *J* = 2.7 Hz, 1H), 6.65 (t, *J* = 2.4 Hz, 1H), 6.40 (t, *J* = 6.5 Hz, 1H), 4.82 (d, *J* = 6.9 Hz, 2H), 2.14 (s, 1H), 1.76 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>): δ 162.7, 145.2, 144.9, 136.2, 129.0, 128.4, 127.6, 126.9, 126.6, 126.03, 123.6, 91.5, 67.3, 29.0; IR (ATR): 3450, 2983, 1719, 1220, 1067, 826, 770, 699 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>17</sub>H<sub>16</sub>Cl<sub>3</sub>NNaO<sub>2</sub>S 425.9860, found: 425.9859; HPLC analysis: Chiralpak IA-3 column (Hexane:<sup>i</sup>PrOH = 95:5, 1.0 mL/min, 40 °C, 220 nm) 11.0 min (minor), 12.8 min (major). The absolute configurations were assigned as (*R*) by analogy with compound **4a**.

### 3. Preparation of Substrates

Allylic substrates **4** were prepared by following the literature procedure.<sup>1</sup>




To a solution of **S1** (1.0 eq.) and trichloroacetonitrile (1.5 eq) in CH<sub>2</sub>Cl<sub>2</sub> (0.2M) was added DBU (0.2 eq) at 0 °C. The resulting solution was stirred for 30 min at the same temperature. Then the residual crude was concentrated and purified by flash column chromatography on silica gel (Hexane/EtOAc = 20/1) to obtain **4** as a colorless oil.

<sup>1</sup> S. Kayal, J. Kikuchi, M. Shimizu, M. Terada, *ACS Catal.* **2019**, *9*, 6846–6850.

#### 4. Determination of the relative and absolute configuration

##### 4-1. The absolute configuration of recovered-4a

The absolute configuration on C4 position of recovered-4a was determined to be *R* by derivatization into the stereochemically known compound **S2**.<sup>2</sup> The stereochemistry of the remaining recovered **4** was assigned by analogy.



To a solution of *recovered-4a* (50 mg, 0.125 mmol, 95% ee) in CH<sub>2</sub>Cl<sub>2</sub> (2.0 mL) was bubbled with O<sub>3</sub> until the solution turned blue at -78 °C (10 min). To the blue solution was added Me<sub>2</sub>S (1.0 mL) and the mixture was slowly warmed to rt. The mixture was concentrated in vacuo to give a residue, which was then washed with H<sub>2</sub>O was added and extracted with EtOAc. The combined EtOAc extracts were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated after filtration. The residual crude was purified by silica gel column chromatography (Hexane/EtOAc = 19/1) to give **S2** (22.6 mg, 80% yield).



##### (*R*)-2-hydroxy-1,2-diphenylpropan-1-one (**S2**)

**S2** 80% yield (22.6 mg); colorless oil; [ $\alpha$ ]<sub>D</sub><sup>26</sup> +174.5 (*c* 0.24, EtOH, 98% ee); R<sub>f</sub> = 0.42 (Hexane/EtOAc = 4/1); <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>):  $\delta$  7.69-7.67 (m, 2H), 7.47-7.44 (m, 3H), 7.39 (t, *J* = 7.9 Hz, 2H), 7.34-7.28 (m, 3H), 4.78 (s, 1H), 1.90 (s, 3H); <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>):  $\delta$  202.1, 142.5, 133.5, 133.1, 130.3, 129.1, 128.4, 128.3, 126.0, 79.2, 26.2; IR (ATR): 3448, 1673, 1447, 1255, 768, 700 cm<sup>-1</sup>; HRMS(ESI) *m/z*: [M+Na]<sup>+</sup> Calcd for C<sub>15</sub>H<sub>14</sub>NaO<sub>2</sub> 249.0886, found: 249.0886; HPLC analysis: Chiralpak IC-3 column (Hexane:<sup>i</sup>PrOH = 98:2, 1.0 mL/min, 40 °C, 220 nm) 13.5 min (major), 14.0 min (minor).


<sup>2</sup> S.-B. D. Sim, M. Wang, Y. Zhao, *ACS Catal.* **2015**, *5*, 3609-3612.

#### 4-2. The absolute configuration of **5a**

According to the following NOE analysis of **5l** and the absolute configuration of **4a**, the absolute configuration of **5a** was assigned to be (2*S*,3*R*). The stereochemistry of the remaining products **5** was assigned by analogy.




COSY (600 MHz,  
CDCl<sub>3</sub>) spectra of **5l**




## 5. Determination of the reaction pathway of the intramolecular $S_N2'$ reaction<sup>3</sup>

To elucidate the mechanism of the present intramolecular  $S_N2'$  reaction, enantioenriched (*S,E*)-**d-2a** containing deuterium at the allylic position was employed. In the proposed deuterated substrate study, the stereochemical relationship between the chirality at the deuterated carbon as well as the geometry of starting (*S,E*)-**d-2a** and the geometry of the migrated double bond, in combination with the newly generated stereogenic center, would offer important information of the reaction pathway. As shown in the following scheme, enantioenriched (*R,Z*)-**d-3a** (95% ee) was obtained in good yield with high (*Z*)-selectivity, clearly suggesting that the *anti*- $S_N2'$  pathway is the rational mechanism for the present intramolecular  $S_N2'$  reaction.



In an oven and vacuum-dried reaction tube, MS 5Å (40.0 mg), catalyst (*R*)-**1a** (12.4 mg, 0.01 mmol, 10 mol%) and  $Ag_2CO_3$  (1.4 mg, 0.005 mmol, 5 mol%) were taken with 0.5 mL of  $Et_2O$ . The reaction mixture was stirred at room temperature for 15 min and then cooled at  $-40\text{ }^\circ\text{C}$ . To the reaction mixture was added a solution of **d-2a** (36.3 mg, 0.1 mmol) in  $Et_2O$  (0.5 mL) at the same temperature. The reaction mixture was stirred for 24 h. The reaction mixture was quenched with  $NEt_3$  (10  $\mu\text{L}$ ) and directly purified by flash column chromatography (Hexane/ $EtOAc = 10:1$ ) to give **d-3a** (14.5 mg) in 72% yield ( $E/Z = 1:>20$ ) with 95% ee.

### (*R,Z*)-2-phenyl-2-(vinyl-2-d)-1-oxaspiro[2.4]heptane (**d-3a**)



**d-3a**


72% yield (14.5 mg); colorless oil;  $[\alpha]_D^{26} +57.9$  (c 0.47,  $CHCl_3$ , 95% ee);  $R_f = 0.71$  (Hexane/ $EtOAc = 4/1$ );  $^1H$  NMR ( $C_6D_6$ , 600MHz)  $\delta$  7.38 (dd,  $J = 8.4, 1.8$  Hz, 1H), 7.20-7.00 (m, 4H), 6.05 (dt,  $J = 10.8, 2.4$  Hz, 1H), 5.14 (d,  $J = 10.8$  Hz, 1H), 1.92-1.84 (m, 1H), 1.78-1.68 (m, 1H), 1.65-1.55 (m, 1H), 1.54-1.44 (m, 1H), 1.42-1.20 (m, 4H);  $^{13}C$  NMR ( $C_6D_6$ , 151MHz)  $\delta$  139.4, 137.7, 130.8, 127.3 (4C), 117.8 (t,  $J = 27.5$  Hz, 1C), 76.9, 67.8, 31.9, 30.5, 25.4, 25.3; IR (ATR) 2922, 2360, 2309, 1732, 1459, 1218, 772  $cm^{-1}$ ; HRMS (FD+)  $m/z$ : [M] Calcd for  $C_{14}H_{15}DO$  201.1264, Found 201.1262; HPLC analysis: Chiralpak OD-3 (Hexane: $iPrOH = 99.3/0.7$ , 1.0 mL/min,  $40\text{ }^\circ\text{C}$ , 220 nm) 4.2 min (minor), 4.5 min (major).

<sup>3</sup> S. Kayal, J. Kikuchi, N. Shinagawa, S. Umemiya, M. Terada, *Tetrahedron* **2021**, 98, 132412.




## 6. Stereochemical assignment of *trans*-5t and calculation of conversion *c* in Table 2, entry 19

Absolute stereochemistry of *trans*-5t was assigned to be (2*R*,3*S*) based on the distribution of the stereochemical outcomes of *cis*- and *trans*-5t and recovered (*Z*)-4t, as shown in the following simulation. In this regard, conversion *c* was calculated using 51% ee for ee<sub>product</sub> averaged at the 2-position of *cis*- and *trans*-5t. The calculation process was shown in the following scheme.




## 7. Large scale experiment



To a mixture of MS 5Å (400 mg), (*R*)-1a (124 mg, 0.1 mmol, 10 mol%) and Ag<sub>2</sub>CO<sub>3</sub> (14 mg, 0.05 mmol, 5 mol%) was added Et<sub>2</sub>O (5.0 mL). The reaction mixture was stirred at room temperature for 15 min and then cooled at 0 °C. To the reaction mixture was added a solution of racemic (*E*)-4a (0.40 g, 1.0 mmol) in Et<sub>2</sub>O (5.0 mL) at the same temperature and the reaction mixture was stirred for 96 h. The reaction mixture was quenched with NEt<sub>3</sub> (100 μL) and directly purified by flash column chromatography (Hexane/EtOAc = 10:1) to give 5a (106 mg, 45%) with 98% ee and (*R*,*E*)-4a (200 mg, 50%) with 87% ee. The enantiomeric excess was determined by chiral stationary phase HPLC analysis.

## 8. Derivatization




To a solution of *cis*-(2*S*,3*R*)-**5a** (23.6 mg, 0.1 mmol, 98% ee) in THF (0.8 mL) and H<sub>2</sub>O (0.2 mL) was added 10-camphorsulfonic acid (CSA) (4.6 mg, 0.02 mmol). The reaction mixture was stirred at 50 °C for 3 h. The reaction was quenched with aq. NaHCO<sub>3</sub> (1 mL) and the aqueous phase was extracted with EtOAc (1 mL) three times. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in *vacuo*. The crude was purified by flash column chromatography (Hexane/EtOAc = 2:1 to 1:1) to give (*S,E*)-**7** in 68% yield with 95% ee. The enantiomeric excess was determined by chiral stationary phase HPLC analysis.

### (*S,E*)-3,4-diphenylpent-2-ene-1,4-diol (**7**)

(*S,E*)-**7**


68% yield (17.3 mg); colorless oil;  $[\alpha]_{\text{D}}^{25} +27.4$  (c 0.79, CHCl<sub>3</sub>, 95% ee);  $R_f = 0.42$  (Hexane/EtOAc = 1/2); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 600MHz)  $\delta$  7.42 (d,  $J = 8.4$  Hz, 2H), 7.32 (t,  $J = 8.4$  Hz, 2H), 7.28-7.15 (m, 4H), 6.74 (dd,  $J = 8.4, 1.2$  Hz, 2H), 6.14 (t,  $J = 6.6$  Hz, 1H), 3.91 (dd,  $J = 6.6, 1.8$  Hz, 2H), 1.71 (s, 3H), 1.60 (bs, 2H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 151MHz)  $\delta$  149.2, 145.7, 136.9, 129.5 (2C), 128.0 (2C), 127.9 (2C), 127.4, 127.0, 125.9, 125.8 (2C), 76.8, 60.5, 28.9; IR (ATR): 3224, 1491, 1447, 1302, 1147, 1136, 1089, 1066, 1021, 979, 902 cm<sup>-1</sup>; HRMS (FD)  $m/z$ : [M]<sup>+</sup> Calcd for C<sub>17</sub>H<sub>18</sub>O<sub>2</sub> 254.1307, found 254.1306; HPLC analysis: Chiralpak IA column (Hexane:<sup>i</sup>PrOH = 90:10, 0.7 mL/min, 30 °C, 220 nm) 16.1 min (major), 17.8 min (minor).



To a solution of (*R,E*)-**4a** (39.8 mg, 0.1 mmol, 94% ee) in THF (1 mL) was added trifluoroacetic acid (TFA) (15  $\mu$ L, 0.2 mmol) at room temperature. The reaction mixture was stirred at that temperature for 30 min. The reaction was quenched with aq. NaHCO<sub>3</sub> (2 mL) and the aqueous phase was extracted with EtOAc (1 mL) three times. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in *vacuo*. To a solution of the crude in MeOH (1 mL) was added potassium carbonate (41 mg, 0.3 mmol) at room temperature. The reaction mixture was stirred at that temperature for 2 h. The reaction was quenched with aq. NH<sub>4</sub>Cl (2 mL) and the aqueous phase was extracted with EtOAc (1 mL) three times. The combined organic layers were washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in *vacuo*. The crude was purified by flash column chromatography (Hexane/EtOAc = 2:1 to 1:1) to give (*R,E*)-**7** in 72% yield with 94% ee. The enantiomeric excess was determined by chiral stationary phase HPLC analysis.


## 9. Main reaction using catalyst (*R*)-**1b**

### 9-1. Reaction of racemic (*E*)-**4a** using (*R*)-**1b**/phenylboronic acid co-catalyst system in chloroform




To a mixture of MS 5Å (40.0 mg), (*R*)-**1b** (5.9 mg, 0.01 mmol, 10 mol%) and PhB(OH)<sub>2</sub> (1.2 mg, 0.01 mmol, 10 mol%) was added chloroform (0.5 mL). The reaction mixture was stirred at room temperature for 15 min. To the reaction mixture was added a solution of (*E*)-**4a** (39.8 mg, 0.1 mmol) in chloroform (0.5 mL) at the same temperature and the reaction mixture was stirred for 4 h. The reaction mixture was quenched with NEt<sub>3</sub> (10 μL) and directly purified by flash column chromatography (Hexane/EtOAc = 10:1) to give *cis*-**5a** and *trans*-**5a** (dr = 61 : 39) in 56% combined yield.

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) spectra of *cis*-**5a** and *trans*-**5a**




9-2. Reaction of racemic (*E*)-**4a** using (*R*)-**1a**/phenylboronic acid co-catalyst system in chloroform



To a mixture of MS 5Å (40.0 mg), (*R*)-**1a** (12.4 mg, 0.01 mmol, 10 mol%) and PhB(OH)<sub>2</sub> (1.2 mg, 0.01 mmol, 10 mol%) was added chloroform (0.5 mL). The reaction mixture was stirred at room temperature for 15 min. To the reaction mixture was added a solution of (*E*)-**4a** (39.8 mg, 0.1 mmol) in chloroform (0.5 mL) at the same temperature and the reaction mixture was stirred for 4 h. The reaction mixture was quenched with NEt<sub>3</sub> (10 μL) and directly purified by flash column chromatography (Hexane/EtOAc = 10:1) to give *cis*-**5a** as a single diastereomer in 12 % yield along with the formation of a significant amount of vinylogous Wagner-Meerwein shift product **6a** in 51% yield.

<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) spectra of rearrangement product **6a**



## 10. DFT Calculation

To acquire mechanistic insights into the present reaction, we conducted DFT calculation (Gaussian 16 package). The model system of bisphosphoric acid (*R*)-**1b** and substrates (*S,E*)-**4a** or (*R,E*)-**4a** were employed. Geometries were optimized and characterized using frequency calculations at the B97D/6-31G(d) level. Gibbs free energies (kcal mol<sup>-1</sup>) in solution phase were calculated using single-point energy calculations at the same level as those for the optimized structures according to the SCRF method based on CPCM ( $\epsilon = 4.335$  for diethyl ether).

### 7.1 Energy profile of the intramolecular S<sub>N</sub>2' reaction of (*S,E*)-**4a** using (*R*)-**1b**

As illustrated in the Figure S1, the reaction energy profile shows that the present intramolecular S<sub>N</sub>2' reaction does not proceed in a synchronous concerted fashion but proceeds in a stepwise pathway, although the energy of the 2nd step is lower than the 1st step.




Figure S1. The potential energy for the sum of (*R*)-**1b** and (*S,E*)-**4a** was set to zero. Geometries were optimized and characterized using frequency calculations at the B97D/631G(d) level. Gibbs free energies (kcal/mol) in solution phase were calculated using single calculations at the same level as those for the optimized structures according to the SCRF method based on CPCM ( $\epsilon = 4.335$  for diethyl ether).

3D structures of the transition states




Figure S2. Transition states of intramolecular  $S_N2'$  reaction of (*S,E*)-**4a** or (*R,E*)-**4a** catalyzed by (*R*)-**1b**. Geometries were optimized and characterized using frequency calculations at the B97D/631G(d) level. Gibbs free energies (kcal/mol) in solution phase were calculated using single calculations at the same level as those for the optimized structures according to the SCRf method based on CPCM ( $\epsilon = 4.335$  for diethyl ether).





















75	6	0	-3.145279	4.120548	2.057812
76	1	0	-3.999136	4.762442	1.833021
77	6	0	-3.240005	2.754480	1.845069
78	1	0	-4.162621	2.324252	1.457172
79	6	0	-2.141200	1.890314	2.124818
80	6	0	1.282501	-0.583593	3.122869
81	6	0	1.734506	-1.609082	2.264055
82	6	0	2.891404	-2.344530	2.536802
83	6	0	3.636581	-2.055632	3.687298
84	1	0	4.543094	-2.625066	3.899220
85	6	0	3.211970	-1.042897	4.563474
86	1	0	3.782240	-0.821503	5.467229
87	6	0	2.044756	-0.322650	4.282707
88	1	0	1.700308	0.455630	4.965667
89	1	0	3.202322	-3.115950	1.835689
90	1	0	-3.354588	0.607171	-5.208005
91	6	0	2.449362	4.534133	-0.620126
92	6	0	1.828067	4.767315	0.617965
93	6	0	3.747530	5.019127	-0.853131
94	6	0	2.503666	5.483180	1.616422
95	1	0	0.827473	4.373955	0.798365
96	6	0	4.423441	5.730208	0.148375
97	1	0	4.235059	4.820272	-1.809959
98	6	0	3.801992	5.965033	1.385836
99	1	0	2.015768	5.663578	2.577208
100	1	0	5.436903	6.093382	-0.033635
101	1	0	4.329597	6.516768	2.166544
102	6	0	1.205034	4.683303	-2.826278
103	1	0	2.050490	5.150852	-3.354229
104	1	0	0.586846	4.134299	-3.548450
105	1	0	0.595342	5.487112	-2.385069

## 11. NMR Charts

$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **4a**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **4b**









$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **4c**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **4d**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **4e**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **4f**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **4g**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **4h**



$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **4i**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **4j**









$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **4k**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **41**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **4m**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **4n**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **4p**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **4q**



$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **4s**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **4t**









$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **5a**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **5b**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **5c**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **5d**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **5f**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **5g**



$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **5h**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **5i**









<sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>) spectra of **5j**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **5k**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **51**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **5m**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **5n**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **5p**



$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **5q**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **5s**









$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **5t**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **7**





$^1\text{H}$  NMR (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (151 MHz,  $\text{CDCl}_3$ ) spectra of **6e**





## 12. HPLC Charts




	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-5a</i>	5.6	6.2	50.1	49.9
(2 <i>S</i> ,3 <i>R</i> )- <b>5a</b>	5.7	6.2	1.0	99.0





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-4a</i>	9.3	10.8	50.1	49.9
<i>(R,E)-4a</i>	9.6	11.0	2.7	97.3



	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-5b</i>	6.0	6.5	50.0	50.0
( <i>2S,3R</i> )- <b>5b</b>	6.1	6.5	2.8	97.2





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac</i> - <b>4b</b>	8.5	10.2	49.6	50.4
( <i>R,E</i> )- <b>4b</b>	8.5	10.1	9.5	90.5





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-5c</i>	8.3	9.3	49.6	50.4
(2 <i>S</i> ,3 <i>R</i> )- <b>5c</b>	8.4	9.1	3.2	96.8









	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-4c</i>	9.8	11.8	50.0	50.0
<i>(R,E)-4c</i>	9.8	11.8	3.9	96.1





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-5d</i>	4.6	4.8	49.2	50.8
<i>(2S,3R)-5d</i>	4.6	4.8	2.9	97.1





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-4d</i>	9.5	11.7	50.3	49.7
<i>(R,E)-4d</i>	9.5	11.6	7.5	92.5





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-4e</i>	14.0	16.8	49.6	50.4
( <i>R,E</i> )- <b>4e</b>	14.2	16.8	16.5	83.5





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-5f</i>	9.0	12.3	49.6	50.4
<i>(2S,3R)-5f</i>	9.3	11.8	2.4	97.6



	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-4f</i>	18.8	19.8	49.2	50.8
<i>(R,E)-4f</i>	18.5	19.4	7.5	92.5





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-5g</i>	4.9	5.6	50.1	49.9
(2 <i>S</i> ,3 <i>R</i> )- <b>5g</b>	4.9	5.4	2.8	97.2





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-4g</i>	8.9	9.9	50.4	49.6
<i>(R,E)-4g</i>	8.7	9.7	10.8	89.2









	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac</i> - <b>5h</b>	6.5	7.3	50.2	49.8
( <i>2S,3R</i> )- <b>5h</b>	6.8	7.4	4.2	95.8





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<b>rac-4h</b>	11.4	14.1	49.9	50.1
<b>(R,E)-4h</b>	11.4	14.2	97.9	2.1





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-5i</i>	5.1	5.5	50.2	49.8
<i>(2S,3R)-5i</i>	5.0	5.4	3.1	96.9





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-4i</i>	10.7	12.2	49.6	50.4
<i>(R,E)-4i</i>	10.8	12.3	21.8	78.2





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-5j</i>	10.3	12.0	49.9	50.1
<b>(2<i>S</i>,3<i>R</i>)-5j</b>	10.0	11.6	4.6	95.4



	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-4j</i>	6.6	7.1	49.6	50.4
<i>(R,E)-4j</i>	6.6	7.1	76.1	23.9





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<b>rac-5k</b>	4.6	5.2	49.9	50.1
<b>(2<i>S</i>,3<i>R</i>)-5k</b>	4.6	5.1	2.3	97.7





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-4k</i>	7.6	9.0	50.2	49.8
<i>(R,E)-4k</i>	8.1	9.0	1.1	98.9









	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac</i> - <b>5I</b>	6.9	7.1	49.6	50.4
(2 <i>S</i> ,3 <i>R</i> )- <b>5I</b>	7.2	7.4	7.2	92.8





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac</i> - <b>4I</b>	12.1	14.5	50.0	50.0
<i>(R,E)</i> - <b>4I</b>	12.1	14.7	6.7	93.3





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-5m</i>	4.8	5.1	49.7	50.3
<i>(2S,3R)-5m</i>	4.8	5.1	96.1	3.9





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<b>rac-4m</b>	10.2	11.8	50.3	49.7
<b>(R,E)-4m</b>	10.2	11.8	21.2	78.8





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-5n</i>	13.0	13.7	49.6	50.4
(2 <i>S</i> ,3 <i>R</i> )- <b>5n</b>	12.8	13.2	2.7	97.3



	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-4n</i>	13.8	15.5	50.1	49.9
<i>(R,E)-4n</i>	13.6	15.4	31.9	68.1





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-5p</i>	4.9	5.2	49.8	50.2
(2 <i>S</i> ,3 <i>R</i> )- <b>5p</b>	4.9	5.1	2.2	97.8





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-4p</i>	8.3	9.5	50.0	50.0
<i>(R,E)-4p</i>	8.3	9.5	23.7	76.3








	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac</i> - <b>5q</b>	10.6	11.5	49.7	50.3
(2 <i>S</i> ,3 <i>R</i> )- <b>5q</b>	11.0	12.0	1.0	99.0





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-4q</i>	10.4	11.3	49.9	50.1
( <i>R,E</i> )- <b>4q</b>	10.3	11.2	26.7	73.3





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-5s</i>	10.5	11.1	49.6	50.4
(2 <i>S</i> ,3 <i>R</i> )- <b>5s</b>	10.4	10.8	9.9	90.1





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-4s</i>	13.8	15.1	50.0	50.0
( <i>R,E</i> )- <b>4s</b>	13.8	15.1	0.1	99.9





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-5t</i> major	9.2	10.6	50.5	49.5
(2 <i>S</i> ,3 <i>S</i> )- <b>5t</b>	9.8	11.8	92.9	7.1



	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-5t</i> minor	7.9	8.8	49.9	50.1
(2 <i>S</i> ,3 <i>S</i> )- <b>5t</b>	7.8	8.8	94.0	6.0




	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-4t</i>	11.1	12.9	50.4	49.6
<i>(R,Z)-4t</i>	11.0	12.8	26.0	74.0





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-7</i>	16.1	17.8	49.7	50.3
<i>(S,E)-7</i>	15.8	17.5	97.6	2.4





	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac-7</i>	16.1	17.8	49.7	50.3
<i>(R,E)-7</i>	17.3	19.7	97.2	2.8



	Retention time (1)	Retention time (2)	% Area (1)	% Area (2)
<i>rac</i> -S2	13.4	14.1	49.7	50.3
( <i>R</i> )-S2	13.3	14.0	98.9	1.1

### 13. Reference

Complete Reference of Gaussian 16 (Ref. 22)

Gaussian 16, Revision C.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. V. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. J. Heyd, E. N. Brothers, K. N. Kudin, V. N. Staroverov, T. A. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. P. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman, and D. J. Fox, Gaussian, Inc., Wallingford CT, 2016.